The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 10, 2015

Filed:

Apr. 29, 2011
Applicants:

Yinxiang Wang, Beijing, CN;

Fenlai Tan, Beijing, CN;

Shaojing HU, Beijing, CN;

Xiangdong Zhao, Beijing, CN;

Cunbo MA, Beijing, CN;

Yanping Wang, Beijing, CN;

Xiaoyan Shen, Beijing, CN;

Lieming Ding, Beijing, CN;

Yunyan HU, Beijing, CN;

Hong Cao, Beijing, CN;

Wei Long, Beijing, CN;

Inventors:

Yinxiang Wang, Beijing, CN;

Fenlai Tan, Beijing, CN;

Shaojing Hu, Beijing, CN;

Xiangdong Zhao, Beijing, CN;

Cunbo Ma, Beijing, CN;

Yanping Wang, Beijing, CN;

Xiaoyan Shen, Beijing, CN;

Lieming Ding, Beijing, CN;

Yunyan Hu, Beijing, CN;

Hong Cao, Beijing, CN;

Wei Long, Beijing, CN;

Assignee:

Betta Pharmaceuticals Co., Ltd., Hangzhou, Zhejiang, CN;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61P 9/10 (2006.01); C07K 14/47 (2006.01); A61P 3/04 (2006.01); A61K 38/22 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61K 38/26 (2006.01); A61P 7/12 (2006.01); C07K 14/605 (2006.01); A61K 38/28 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 38/00 (2013.01);
Abstract

Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar.


Find Patent Forward Citations

Loading…